Discussion of the two biologies of DLBCL – the GCB and ABC subtype and potential targeted therapies
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al.
Current projects at City of Hope: CAR T-cells, vaccines and a novel nuceloside analogue
Panel discussion on T-cell lymphoma: current status of therapy and progress
Elaine Jaffe et al.
Panel discussion on immune therapies for lymphoma – CAR T-cell therapy and the question of cure
Anas Younes et al.